Floatz Rating
B63/100
Confidence
Indicative
Sponsor
National Cancer Institute, Naples
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07302451CT.gov REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients) | — | Active Not Recruiting | — | — | — |
NCT06631521CT.gov Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer | — | Recruiting | — | — | — |
NCT06499870CT.gov Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial | — | Recruiting | — | — | — |
NCT05679388CT.gov A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients | — | Terminated | — | — | — |
NCT05050084CT.gov Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | — | Active Not Recruiting | — | — | — |
NCT04513717CT.gov Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | — | Active Not Recruiting | — | — | — |
NCT04423211CT.gov Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Relugolix (this asset) | National Cancer Institute, Naples | P3 | B · 63 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Prednisone | Mayo Clinic | P3 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
| Goserelin | CancerCare Manitoba | P3 | BB |
| Bicalutamide | OHSU Knight Cancer Institute | P3 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Relugolix
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P3 | BB · 65 |
| Prostate Carcinoma | — | P3 | BB · 64 |
| Metastatic Prostate Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Relugolix in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/relugolix-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →